NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE

# SAVINGS AND COVERAGE

The NanoKnife System is the only function-preserving, minimally invasive therapy that uses electricity to destroy prostate tumors[1]

US/ON/BR/3735 Rev 01 12/2025 INDIVIDUAL RESULTS MAY VARY

# SAVINGS AND COVERAGE

The NanoKnife System is designed to not only help preserve your quality of life, but also to lessen the financial impact of prostate care.

Every patient's financial situation is unique, but costs often come from two areas:

## DIRECT COSTS

› procedure fees, medical visits, imaging, medications (can be covered by insurance)

## INDIRECT COSTS

› missed work, travel, home or family care, long-term side effect management (typically out of pocket)

## SAVINGS WITH THE NANOKNIFE PROCEDURE

*A single NanoKnife System patient can avoid up to $4,350 - $12,900 in indirect costs compared to radiation or surgery.*

### Minimize Downtime, Maximize Productivity

- Return to work twice as fast, avoiding thousands in lost wages[2,3,4,5]
  *based on U.S. Bureau of Labor Statistics median week earnings in the US.*

### Less Travel, More Savings

- Avoid 50% travel costs, with 550–12,500 fewer miles traveled[2,6]
  *extrapolated from average travel to surgical center by car and public transport*

### Lower Complication Costs

- About 60% less spent on follow-up supplies and care[2]
  *based on complication data extrapolated by IRE, radical proctectomy, and radiation patients*

US/ON/BR/3735 Rev 01 12/2025 INDIVIDUAL RESULTS MAY VARY.

# UNDERSTANDING INSURANCE COVERAGE

Coverage details vary depending on your insurance plan, facility, and physician. Consult your physician's billing office with any questions.

As of January 1, 2026, Irreversible Electroporation advanced from a Category III to a Category I CPT Code. This advancement reflects that the procedure has achieved sufficient clinical evidence, utilization, and professional acceptance to be recognized as an established medical service, supporting broader potential for insurance coverage.

## WE'RE HERE TO HELP

You don't have to figure this out alone, we're here to support you every step of the way:

- **Patient Navigator**
  A free resource to answer your questions, talk through next steps, and connect you with a physician near you.
  Email: NanoNavigator@angiodynamics.com or Phone: 1-855-567-NANO
- **Reimbursement Support:**
  Our team works directly with your doctor's office to navigate insurance coverage and billing. Email: Reimbursement@angiodynamics.com




## NANOKNIFE.COM

## WHAT'S NEXT?

**Use the physician locator** to find a physician who utilizes the NanoKnife System near you: https://nanoknife.com/physician-locator

For personalized help in your journey, contact our Patient Navigator by phone at 1-855-567-NANO or by email at NanoNavigator@angiodynamics.com.

US/ON/BR/3735 Rev 01 12/2025 INDIVIDUAL RESULTS MAY VARY

**INDIVIDUAL RESULTS MAY VARY.**

**This material provides general information about our medical device and its potential benefits. However, it is essential to consult with a qualified healthcare professional (such as a doctor or specialist) before using this device. Individual health conditions and medical history can vary, and only a qualified healthcare professional can assess whether this device is suitable for your specific needs.**

**REFERENCES**


1. Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localized prostate cancer. BJU Int. 2023;131 Suppl 4:6-13. doi:10.1111/bju.15946

2. Data on file – Alkemi Economic Model on Patient Impact and Insurance

3. Okhawere KE, Shih IF, Lee SH, Li Y, Wong JA, Badani KK. Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy. JAMA Netw Open. 2021 Mar 1;4(3):e212265. doi: 10.1001/jamanetworkopen.2021.2265. PMID: 33749767; PMCID: PMC7985723.

4. Sveistrup J, Mortensen OS, Rosenschöld PM, Engelholm SA, Petersen PM. Employment and sick leave in patients with prostate cancer before, during and after radiotherapy. Scand J Urol. 2016 Jun;50(3):164-9. doi: 10.3109/21681805.2015.1119190. Epub 2016 Jan 12. PMID: 26754420

5. Usual Weekly Earnings of Wage and Salary Workers First Quarter 2025, Bureau of Labor Statistics, April 16, 2025

6. Flannigan et all, Risk of Hospitalization Following Treatment for Prostate Cancer. BJU Int. 2017 July ; 120(1): 48–55. doi:10.1111/bju.13647.


**RISK INFORMATION:**

The NanoKnife System must be operated by properly qualified personnel only.

**CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.**

Refer to directions for use and/or user manual provided with the product for complete instructions, warnings, precautions, possible adverse effects and contraindications prior to use of the product.

**INDICATIONS FOR USE:**

**US:** The NanoKnife System With six outputs is indicated for surgical ablation of soft tissue, including prostate tissue.

**Canada:** The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability.

**EU:** The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.

**Contraindications:**

- Ablation procedures using the NanoKnife System are contraindicated in the following cases:
- Ablation of lesions in the thoracic area in the presence of implanted cardiac pacemakers or defibrillators
- Ablation of lesions in the vicinity of implanted electronic devices or implanted devices with metal parts.
- Ablation of lesions of the eyes, including the eyelids.
- Patient history of Epilepsy or Cardiac Arrhythmia
- Recent history of Myocardial Infarction.

NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE

angiodynamics